Hepatic dysfunction in children with acute lymphoblastic leukemia in remission: Relation to hepatitis infection

Meir, Hadir; Balawi, Ibrahin; Nayel, Hala; Karaksy, Hanaa El; Haddad, Alla El

doi:10.1002/mpo.1111

Cited by 15 publications

(8 citation statements)

References 24 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HCV prevalence among hepatocellular carcinoma (HCC) cases ranged between 61.0% and 90.3%, with a higher prevalence observed among rural versus urban populations [117]. Three studies were conducted among pediatric cancer patients [81,118,119]. HCV prevalence among children with leukemia was 19.0% [118].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis

et al. 2013

View full text Add to dashboard Cite

BackgroundEgypt has the highest prevalence of hepatitis C virus (HCV) in the world, estimated nationally at 14.7%. Our study’s objective was to delineate the evidence on the epidemiology of HCV infection among the different population groups in Egypt, and to draw analytical inferences about the nature of HCV transmission in this country.MethodsWe conducted a systematic review of all data on HCV prevalence and incidence in Egypt following PRISMA guidelines. The main sources of data included PubMed and Embase databases. We also used a multivariate regression model to infer the temporal trend of HCV prevalence among the general population and high risk population in Egypt.ResultsWe identified 150 relevant records, four of which were incidence studies. HCV incidence ranged from 0.8 to 6.8 per 1,000 person-years. Overall, HCV prevalence among pregnant women ranged between 5-15%, among blood donors between 5-25%, and among other general population groups between 0-40%. HCV prevalence among multi-transfused patients ranged between 10-55%, among dialysis patients between 50-90%, and among other high risk populations between 10% and 85%. HCV prevalence varied widely among other clinical populations and populations at intermediate risk. Risk factors appear to be parenteral anti-schistosomal therapy, injections, transfusions, and surgical procedures, among others. Results of our time trend analysis suggest that there is no evidence of a statistically significant decline in HCV prevalence over time in both the general population (p-value: 0.215) and high risk population (p-value: 0.426).ConclusionsEgypt is confronted with an HCV disease burden of historical proportions that distinguishes this nation from others. A massive HCV epidemic at the national level must have occurred with substantial transmission still ongoing today. HCV prevention in Egypt must become a national priority. Policymakers, and public health and medical care stakeholders need to introduce and implement further prevention measures targeting the routes of HCV transmission.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Three studies were conducted among pediatric cancer patients [81,118,119]. HCV prevalence among children with leukemia was 19.0% [118]. HCV prevalence among patients with pediatric malignancies who had just ended chemotherapy was 39.6% [119].…”

Section: Resultsmentioning

confidence: 99%

The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Patients were evaluated for occurrence of any complications, for example, haematological complications like bone marrow (BM) hypoplasia (BM cellularity less than 30 000 at the end of either induction or CNS intensification phases), febrile neutropenia, need for blood or platelet transfusions (hemoglobin level less than 8 gm/dL and platelet count less than 20 000/cmm, resp. ), and toxic hepatitis (defined by elevation of liver enzymes, 2 to 3 folds after chemotherapy, with the exclusion of viral hepatitis and return to the normal range after suspending chemotherapy [10]).…”

Section: Methodsmentioning

confidence: 99%

Vitamin E and N-Acetylcysteine as Antioxidant Adjuvant Therapy in Children with Acute Lymphoblastic Leukemia

Al‐Tonbary

Al-Haggar

El-Ashry

et al. 2009

Advances in Hematology

View full text Add to dashboard Cite

Although cancer therapies have experienced great success nowadays, yet the associated toxic response and free radicals formation have resulted in significant number of treatment-induced deaths rather than disease-induced fatalities. Complications of chemotherapy have forced physicians to study antioxidant use as adjunctive treatment in cancer. This study aimed to evaluate the antioxidant role of vitamin E and N-acetyl cysteine (NAC) in overcoming treatment-induced toxicity in acute lymphoblastic leukaemia (ALL) during the intensive period of chemo-/radiotherapy, almost the first two months of treatment. Forty children newly diagnosed with ALL were enrolled in this study. Twenty children (group I) have taken vitamin E and NAC supplementations with chemotherapy and the other twenty children (group II) have not taken any adjuvant antioxidant therapy. They were evaluated clinically for the occurrence of complications and by the laboratory parameters (blood levels of glutathione peroxidase (Glu.PX) antioxidant enzyme, malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), liver enzymes, and bone marrow picture). Results revealed reduced chemotherapy and radiotherapy toxicity as evidenced by decreasing level of MDA, increasing level of Glu.Px and decreased occurrence of toxic hepatitis, haematological complications, and need for blood and platelet transfusions in group I compared to group II. We can conclude that vitamin E and NAC have been shown to be effective as antioxidant adjuvant therapy in children with ALL to reduce chemo-/radiotherapy-related toxicities during the initial period of treatment.

show abstract

“…Risk for developing chronic hepatitis in children with cancer may be related to multiple blood transfusions and immunosuppression secondary to chemotherapy and radiotherapy [12].…”

Section: Discussion:-mentioning

confidence: 99%

Change in Immunological Memory of Hepatitis B Vaccine After Chemotherapy; A Real Problem in Pediatric Cancer Patients.

ElAkhras¹,

Mohamed²,

Zakaria³

et al. 2016

IJAR

View full text Add to dashboard Cite

Hepatic dysfunction in children with acute lymphoblastic leukemia in remission: Relation to hepatitis infection

Cited by 15 publications

References 24 publications

The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis

The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis

Vitamin E and N-Acetylcysteine as Antioxidant Adjuvant Therapy in Children with Acute Lymphoblastic Leukemia

Change in Immunological Memory of Hepatitis B Vaccine After Chemotherapy; A Real Problem in Pediatric Cancer Patients.

Contact Info

Product

Resources

About